用于心脏再生的工程组织：现状与未来展望
Engineered Tissue for Cardiac Regeneration: Current Status and Future Perspectives.
作者信息
Li Junjun, Liu Li, Zhang Jingbo, Qu Xiang, Kawamura Takuji, Miyagawa Shigeru, Sawa Yoshiki
机构信息
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.
Cardiovascular Division, Osaka Police Hospital, Tennoji, Osaka 543-0035, Japan.
出版信息
Bioengineering (Basel). 2022 Oct 22;9(11):605. doi: 10.3390/bioengineering9110605.
Heart failure (HF) is the leading cause of death worldwide. The most effective HF treatment is heart transplantation, the use of which is restricted by the limited supply of donor hearts. The human pluripotent stem cell (hPSC), including human embryonic stem cell (hESC) and the induced pluripotent stem cells (hiPSC), could be produced in an infinite manner and differentiated into cardiomyocytes (CMs) with high efficiency. The hPSC-CMs have, thus, offered a promising alternative for heart transplant. In this review, we introduce the tissue-engineering technologies for hPSC-CM, including the materials for cell culture and tissue formation, and the delivery means into the heart. The most recent progress in clinical application of hPSC-CMs is also introduced. In addition, the bottleneck limitations and future perspectives for clinical translation are further discussed.
心力衰竭（HF）是全球主要的死亡原因。最有效的HF治疗方法是心脏移植，但供体心脏供应有限限制了其应用。人多能干细胞（hPSC），包括人类胚胎干细胞（hESC）和诱导多能干细胞（hiPSC），可以无限量产生并高效分化为心肌细胞（CMs）。因此，hPSC-CMs为心脏移植提供了一个有前景的替代方案。在本综述中，我们介绍了用于hPSC-CM的组织工程技术，包括细胞培养和组织形成的材料以及心脏内的递送方式。还介绍了hPSC-CMs临床应用的最新进展。此外，进一步讨论了临床转化的瓶颈限制和未来前景。
Zotero 插件